Spark Therapeutics has sold a priority review voucher, entitling the holder to a faster six-month FDA drug review, to Ireland’s Jazz Pharmaceuticals for $110m, a fraction of the price these ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...

The therapy may be eligible for a rare pediatric disease priority review voucher (PRV) if approved. Cyprium would retain ownership of this voucher, which could be used for a subsequent marketing ...

A decline in R&D investment in neglected tropical diseases threatens progress toward critical targets. For over 20 years, one ...